Synthorx, Inc.
https://synthorx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synthorx, Inc.
Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value
After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses.
Sanofi Maintains Growth Streak But Oncology Pipeline Renewal Efforts Stall
The French major saw strong Q3 sales and raised its business guidance accordingly, but the discontinuation of an early-stage trial has added to a growing list of setbacks the firm has faced in reviving its oncology pipeline.
Ex-Sanofi Partnering Chief Wants AI Start-Up Owkin To Be Industry Leader
Having led $30bn of acquisitions of companies at Sanofi, the new challenge for its former global head of partnering is to help make Owkin, “the most disruptive AI biotech company in the world,” he tells Scrip.
Capstan Launches, Backed By Big Names And Big Pharma, To Pioneer In Vivo Cell Therapies
The start-up, founded on science from the University of Pennsylvania, announced a $102m series A financing and the appointment of former Silverback CEO Laura Shawver as CEO.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET